Cobimetinib

An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A pancreatic ductal adenocarcinoma (PDAC), obtained from a patient, was grown orthotopically in the pancreatic tail of nude mice… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
To the Editor: During an evaluation for gastroesophageal reflux disease, a 60-year-old man with a 7-year history of fatigue was… (More)
  • figure 1
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
Melanoma is a recalcitrant disease. The present study used a patient-derived orthotopic xenograft (PDOX) model of melanoma to… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
To characterize cobimetinib pharmacokinetics and evaluate impact of clinically relevant covariates on cobimetinib… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Addition of a MEK inhibitor to a BRAF inhibitor enhances tumour growth inhibition, delays acquired resistance, and… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2014
Review
2014
BACKGROUND The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by… (More)
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2014
2014
Cobimetinib is a MEK inhibitor currently in clinical trials as an anticancer agent. The objectives of this study were to… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of the MAPK pathway. As these tumours… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Cobimetinib is a potent and highly selective inhibitor of MEK1/2. Since cobimetinib exhibited absorption variability in cancer… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?